Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6, viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

中文翻译：

---

感染 SARS-CoV-2 Omicron 变体的免疫功能低下患者治疗后 Sotrovimab 耐药性和病毒持久性

在 47 名接受 sotrovimab 治疗的免疫功能低下患者中评估了病毒进化。治疗后 SARS-CoV-2 的测序在 16 例中成功。6 例记录了与 sotrovimab 耐药性相关的突变，5 例在 30 天后病毒复制仍在继续。可能需要联合抗体治疗以避免免疫功能低下患者的获得性耐药性。